> 首页 > 产品 > 一抗 > 精选抗体 > Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab)

Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab)

Recombinant Antibody

Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) is 98.7%, determined by SEC-HPLC.
Human TNFRSF12A / TWEAKR / CD266 HEK293 Cell Line were stained with Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 0.04694 ug/mL.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q9NP84
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	13911 Da

Additional Information
Target/Specificity	TNFRSF12A / TWEAKR / CD266
Endotoxin	< 0.001EU/ µg,determined by LAL method.
Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.

Protein Information
Name	TNFRSF12A
Synonyms	FN14
Function	Receptor for TNFSF12/TWEAK. Weak inducer of apoptosis in some cell types. Promotes angiogenesis and the proliferation of endothelial cells. May modulate cellular adhesion to matrix proteins.
Cellular Location	Membrane; Single-pass type I membrane protein.
Tissue Location	Highly expressed in heart, placenta and kidney. Intermediate expression in lung, skeletal muscle and pancreas

Research Areas

Application Protocols

Provided below are standard protocols that you may find useful for product applications.

Western Blot Protocol

Blocking Peptides Protocol

Dot Blot Protocol

Immunohistochemistry Protocol

Immunofluorescence Protocol

Immunoprecipitation Protocol

Flow Cytomety Protocol

Cell Culture Protocol